157 related articles for article (PubMed ID: 15569982)
1. Differential radiosensitization in DNA mismatch repair-proficient and -deficient human colon cancer xenografts with 5-iodo-2-pyrimidinone-2'-deoxyribose.
Seo Y; Yan T; Schupp JE; Colussi V; Taylor KL; Kinsella TJ
Clin Cancer Res; 2004 Nov; 10(22):7520-8. PubMed ID: 15569982
[TBL] [Abstract][Full Text] [Related]
2. Preclinical evaluation of 5-iodo-2-pyrimidinone-2'-deoxyribose as a prodrug for 5-iodo-2'-deoxyuridine-mediated radiosensitization in mouse and human tissues.
Kinsella TJ; Kunugi KA; Vielhuber KA; Potter DM; Fitzsimmons ME; Collins JM
Clin Cancer Res; 1998 Jan; 4(1):99-109. PubMed ID: 9516958
[TBL] [Abstract][Full Text] [Related]
3. Preclinical toxicity and efficacy study of a 14-day schedule of oral 5-iodo-2-pyrimidinone-2'-deoxyribose as a prodrug for 5-iodo-2'-deoxyuridine radiosensitization in U251 human glioblastoma xenografts.
Kinsella TJ; Vielhuber KA; Kunugi KA; Schupp J; Davis TW; Sands H
Clin Cancer Res; 2000 Apr; 6(4):1468-75. PubMed ID: 10778979
[TBL] [Abstract][Full Text] [Related]
4. Schedule-dependent drug effects of oral 5-iodo-2-pyrimidinone-2'-deoxyribose as an in vivo radiosensitizer in U251 human glioblastoma xenografts.
Seo Y; Yan T; Schupp JE; Radivoyevitch T; Kinsella TJ
Clin Cancer Res; 2005 Oct; 11(20):7499-507. PubMed ID: 16243824
[TBL] [Abstract][Full Text] [Related]
5. An in vivo comparison of oral 5-iodo-2'-deoxyuridine and 5-iodo-2-pyrimidinone-2'-deoxyribose toxicity, pharmacokinetics, and DNA incorporation in athymic mouse tissues and the human colon cancer xenograft, HCT-116.
Kinsella TJ; Kunugi KA; Vielhuber KA; McCulloch W; Liu SH; Cheng YC
Cancer Res; 1994 May; 54(10):2695-700. PubMed ID: 8168099
[TBL] [Abstract][Full Text] [Related]
6. 5-iodo-2-pyrimidinone-2'-deoxyribose-mediated cytotoxicity and radiosensitization in U87 human glioblastoma xenografts.
Kinsella TJ; Kinsella MT; Seo Y; Berk G
Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1254-61. PubMed ID: 17967315
[TBL] [Abstract][Full Text] [Related]
7. IPdR: a novel oral radiosensitizer.
Saif MW; Berk G; Cheng YC; Kinsella TJ
Expert Opin Investig Drugs; 2007 Sep; 16(9):1415-24. PubMed ID: 17714027
[TBL] [Abstract][Full Text] [Related]
8. Phase I and Pharmacology Study of Ropidoxuridine (IPdR) as Prodrug for Iododeoxyuridine-Mediated Tumor Radiosensitization in Advanced GI Cancer Undergoing Radiation.
Kinsella T; Safran H; Wiersma S; DiPetrillo T; Schumacher A; Rosati K; Vatkevich J; Anderson LW; Hill KD; Kunos C; Collins JM
Clin Cancer Res; 2019 Oct; 25(20):6035-6043. PubMed ID: 31337643
[TBL] [Abstract][Full Text] [Related]
9. Preclinical study of the systemic toxicity and pharmacokinetics of 5-iodo-2-deoxypyrimidinone-2'-deoxyribose as a radiosensitizing prodrug in two, non-rodent animal species: implications for phase I study design.
Kinsella TJ; Schupp JE; Davis TW; Berry SE; Hwang HS; Warren K; Balis F; Barnett J; Sands H
Clin Cancer Res; 2000 Sep; 6(9):3670-9. PubMed ID: 10999760
[TBL] [Abstract][Full Text] [Related]
10. Enhanced radiosensitization with gemcitabine in mismatch repair-deficient HCT116 cells.
Robinson BW; Im MM; Ljungman M; Praz F; Shewach DS
Cancer Res; 2003 Oct; 63(20):6935-41. PubMed ID: 14583494
[TBL] [Abstract][Full Text] [Related]
11. The mismatch repair protein, hMLH1, mediates 5-substituted halogenated thymidine analogue cytotoxicity, DNA incorporation, and radiosensitization in human colon cancer cells.
Berry SE; Garces C; Hwang HS; Kunugi K; Meyers M; Davis TW; Boothman DA; Kinsella TJ
Cancer Res; 1999 Apr; 59(8):1840-5. PubMed ID: 10213489
[TBL] [Abstract][Full Text] [Related]
12. Probabilistic modeling of DNA mismatch repair effects on cell cycle dynamics and iododeoxyuridine-DNA incorporation.
Gurkan E; Schupp JE; Aziz MA; Kinsella TJ; Loparo KA
Cancer Res; 2007 Nov; 67(22):10993-1000. PubMed ID: 18006845
[TBL] [Abstract][Full Text] [Related]
13. The interaction between two radiosensitizers: 5-iododeoxyuridine and caffeine.
Seo Y; Yan T; Schupp JE; Yamane K; Radivoyevitch T; Kinsella TJ
Cancer Res; 2006 Jan; 66(1):490-8. PubMed ID: 16397265
[TBL] [Abstract][Full Text] [Related]
14. Effect of H(2)O(2) on cell cycle and survival in DNA mismatch repair-deficient and -proficient cell lines.
Chang DK; Goel A; Ricciardiello L; Lee DH; Chang CL; Carethers JM; Boland CR
Cancer Lett; 2003 Jun; 195(2):243-51. PubMed ID: 12767533
[TBL] [Abstract][Full Text] [Related]
15. Selective radiosensitization of drug-resistant MutS homologue-2 (MSH2) mismatch repair-deficient cells by halogenated thymidine (dThd) analogues: Msh2 mediates dThd analogue DNA levels and the differential cytotoxicity and cell cycle effects of the dThd analogues and 6-thioguanine.
Berry SE; Davis TW; Schupp JE; Hwang HS; de Wind N; Kinsella TJ
Cancer Res; 2000 Oct; 60(20):5773-80. PubMed ID: 11059773
[TBL] [Abstract][Full Text] [Related]
16. Implantable biodegradable polymers for IUdR radiosensitization of experimental human malignant glioma.
Williams JA; Dillehay LE; Tabassi K; Sipos E; Fahlman C; Brem H
J Neurooncol; 1997 May; 32(3):181-92. PubMed ID: 9049879
[TBL] [Abstract][Full Text] [Related]
17. Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses.
Meyers M; Wagner MW; Hwang HS; Kinsella TJ; Boothman DA
Cancer Res; 2001 Jul; 61(13):5193-201. PubMed ID: 11431359
[TBL] [Abstract][Full Text] [Related]
18. Targeting DNA mismatch repair for radiosensitization.
Berry SE; Kinsella TJ
Semin Radiat Oncol; 2001 Oct; 11(4):300-15. PubMed ID: 11677655
[TBL] [Abstract][Full Text] [Related]
19. Antisense inhibition of hMLH1 is not sufficient for loss of DNA mismatch repair function in the HCT116+chromosome 3 cell line.
Chauhan DP; Yang Q; Carethers JM; Marra G; Chang CL; Chamberlain SM; Boland CR
Clin Cancer Res; 2000 Oct; 6(10):3827-31. PubMed ID: 11051225
[TBL] [Abstract][Full Text] [Related]
20. Mismatched nucleotides as the lesions responsible for radiosensitization with gemcitabine: a new paradigm for antimetabolite radiosensitizers.
Flanagan SA; Robinson BW; Krokosky CM; Shewach DS
Mol Cancer Ther; 2007 Jun; 6(6):1858-68. PubMed ID: 17575114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
